* EQRx Inc EQRX.OQ EQRX.O is expected to report
results on May
13.
* Refinitiv's mean analyst estimate for EQRx Inc is for a
loss
of 24 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is "Buy".
* Wall Street's median 12-month price target for EQRx Inc is
$5.6, above its last closing price of $3.35.
This summary was machine generated May 11 at 13:08 GMT. All
figures in US dollars unless otherwise stated